We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+67.45%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$315M
Cap. Flow
-$130M
Cap. Flow %
-5.88%
Top 10 Hldgs %
38.34%
Holding
95
New
23
Increased
27
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$74.6M
2
ABVX
Abivax
ABVX
+$61.3M
3
BDX icon
Becton Dickinson
BDX
+$55.7M
4
DXCM icon
DexCom
DXCM
+$51.4M
5
RGEN icon
Repligen
RGEN
+$48.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$108M
2
CYTK icon
Cytokinetics
CYTK
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$84M
4
QURE icon
uniQure
QURE
+$63.1M
5
KALV
KalVista Pharmaceuticals
KALV
+$54.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$119M 5.39%
600,000
+400,000
+200% +$74.6M
ACLX
2
DELISTED
Arcellx
ACLX
$103M 4.63%
1,250,000
-1,500,000
-55% -$108M
NUVL
3
DELISTED
Nuvalent
NUVL
$95.1M 4.3%
1,100,000
+25,000
+2% +$1.98M
ABVX
4
Abivax
ABVX
$10.8B
$84.9M 3.83%
+1,000,000
New +$61.3M
ALC icon
5
Alcon
ALC
$33.7B
$82M 3.7%
1,100,000
+575,000
+110% +$48M
BCAX
6
Bicara Therapeutics
BCAX
$1.77B
$80.5M 3.64%
5,100,000
+100,000
+2% +$1.12M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$76.8M 3.47%
9,750,000
-2,150,000
-18% -$15.3M
GMED icon
8
Globus Medical
GMED
$10.9B
$71.6M 3.23%
1,250,000
+750,000
+150% +$43.2M
IONS icon
9
Ionis Pharmaceuticals
IONS
$9.14B
$70.3M 3.18%
1,075,000
+575,000
+115% +$28.1M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$16.1B
$65.9M 2.98%
500,000
-700,000
-58% -$84M
BDX icon
11
Becton Dickinson
BDX
$45.8B
$60.8M 2.75%
325,000
+300,000
+1,200% +$55.7M
SRRK icon
12
Scholar Rock
SRRK
$5.92B
$55.9M 2.52%
1,500,000
– –
IMTX icon
13
Immatics
IMTX
$1.19B
$54.1M 2.44%
6,350,000
+100,000
+2% +$616K
RGEN icon
14
Repligen
RGEN
$8.2B
$53.5M 2.41%
+400,000
New +$48.6M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.55B
$46.4M 2.1%
1,180,000
-2,020,000
-63% -$51.6M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$12B
$45M 2.03%
830,000
+330,000
+66% +$18.9M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.28B
$44.2M 1.99%
1,100,000
-900,000
-45% -$31.7M
DXCM icon
18
DexCom
DXCM
$28.9B
$43.7M 1.98%
+650,000
New +$51.4M
CYTK icon
19
Cytokinetics
CYTK
$10.8B
$39.8M 1.8%
725,000
-2,250,000
-76% -$92.7M
BIIB icon
20
Biogen
BIIB
$30.4B
$38.5M 1.74%
+275,000
New +$37.2M
CDTX
21
DELISTED
Cidara Therapeutics
CDTX
$38.3M 1.73%
400,000
-100,000
-20% -$6.38M
ATXS
22
DELISTED
Astria Therapeutics
ATXS
$36.1M 1.63%
4,956,000
+434,000
+10% +$2.94M
DYN icon
23
Dyne Therapeutics
DYN
$4.28B
$35.1M 1.59%
2,775,000
+2,047,500
+281% +$23.4M
TYRA icon
24
Tyra Biosciences
TYRA
$1.84B
$33.9M 1.53%
2,425,000
-230,000
-9% -$2.62M
ABT icon
25
Abbott
ABT
$187B
$33.5M 1.51%
250,000
+75,000
+43% +$9.85M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Vestal Point Capital held 95 positions worth $2.21B, up 17% from $1.9B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Vestal Point Capital withdrew a net $130M in Q3 2025, closing 14 positions and reducing 21 holdings. Its most notable exit was GE HealthCare, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Abivax worth $84.9M.

  • Vestal Point Capital's largest Q3 2025 buy was Abivax: 1,000,000 shares worth $84.9M.
  • Vestal Point Capital added most to Ascendis Pharma A/S in Q3 2025, an estimated $74.6M increase.
  • Vestal Point Capital's biggest Q3 2025 reduction was Arcellx, cutting an estimated $108M.
  • Vestal Point Capital fully exited GE HealthCare in Q3 2025, selling an estimated $51.8M.
  • Vestal Point Capital's ten largest holdings make up 38% of its $2.21B portfolio in Q3 2025.
  • Vestal Point Capital opened 23 new positions and closed 14 in Q3 2025.
  • Vestal Point Capital's portfolio value rose 17% quarter-over-quarter to $2.21B.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.